Pulmatrix

PULM · NASDAQ

$1.43+$0.01 (+0.70%)TodayMarket closed ·
Prev close $1.42

Latest news

  • Press releasePRNewswire

    Are MGLD, NRIM, PULM Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    ACT NOW: The M&A Class Action Firm Is Investigating the Merger--LXP, LXFR, NRIM, and PULM

  • Press releaseGlobe Newswire

    Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

  • Press releasePRNewswire

    Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN

  • Press releasePRNewswire

    Pulmatrix Announces First Quarter 2026 Financial Results

  • Press releasePRNewswire

    Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

  • Press releaseBusiness Wire

    PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releasePRNewswire

    Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

  • News

    12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

  • Press releasePRNewswire

    Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

  • Press releasePRNewswire

    Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

  • Press releasePRNewswire

    Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releasePRNewswire

    Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • News

    Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY

  • Press releasePRNewswire

    Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders

  • Press releaseBusiness Wire

    PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

  • Press releasePRNewswire

    Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders

  • Press releaseBusiness Wire

    PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders

  • Press releaseBusiness Wire

    PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

  • Press releaseBusiness Wire

    Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders

  • Press releaseBusiness Wire

    PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

  • Press releasePRNewswire

    Pulmatrix and Cullgen Announce Proposed Merger

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.